PHT Pharma
  • Home
  • About PH&T
  • Our Products
  • Therapeutic Areas
  • Contacts
  • Decrease font size
  • Reset font size to default
  • Increase font size
News Archive
Title Filter     Display # 
# Article Title
1 Zydus Cadila succesfully launched Turbospin licensed by PH&T
2 PH&T at CPhI 2010
3 PH&T and STADA Asia announce their agreement for Latanoprost and Alfuzosin
4 Exemestane significantly reduces risk of breast cancer
5 Exemestane PH&T proved bioequivalent to Aromasin (Pfizer)
6 Alfuzosin PH&T 10 mg. prolonged release tablets has been registered in Philippines by STADA
7 Epoprostenol PH&T received Marketing Authorization
8 Somatostatin PH&T Vietnam
9 Latanoprost showed full therapeutical equivalence
10 READ MORE NEWS
 

News Archive

  • Epoprostenol PH&T received Marketing Authorization
  • PH&T and STADA Asia announce their agreement for Latanoprost and Alfuzosin
  • Exemestane significantly reduces risk of breast cancer
  • Latanoprost showed full therapeutical equivalence
  • Zydus Cadila succesfully launched Turbospin licensed by PH&T
  • Alfuzosin PH&T 10 mg. prolonged release tablets has been registered in Philippines by STADA
  • Somatostatin PH&T Vietnam
  • PH&T at CPhI 2010
  • Exemestane PH&T proved bioequivalent to Aromasin (Pfizer)
  • READ MORE NEWS

PH&T SpA - P.IVA: 09138720157

  • Privacy
  • Disclaimer
  • Copyright
  • Site Map
  • Useful links
  • WebProject by EBS